Durability and Outcome of Initial Antiretroviral Treatments Received during 2000-2005 by Patients in the Swiss HIV Cohort Study by Vo, Thi Tuyet Nhung et al.
Durability and Outcome of Initial Antiretroviral
Treatments Received during 2000–2005 by Patients
in the Swiss HIV Cohort Study
Thi Tuyet Nhung Vo,1 Bruno Ledergerber,2 Olivia Keiser,3 Bernard Hirschel,5 Hansjakob Furrer,4 Manuel Battegay,6
Matthias Cavassini,7 Enos Bernasconi,8 Pietro Vernazza,9 Rainer Weber,2 and the Swiss HIV Cohort Studya
1VCHAP Project, Tropical Disease Hospital, Ho Chi Minh City, Vietnam; and 2Division of Infectious Diseases and Hospital Epidemiology, University
Hospital, Zurich, 3Institute of Social and Preventive Medicine, University of Bern, and 4Division of Infectious Diseases, University Hospital, Berne,
5Division of Infectious Diseases, University Hospital, Geneva, 6Division of Infectious Diseases, University Hospital, Basel, 7Division of Infectious Diseases,
University Hospital, Lausanne, 8Ospedale Regionale, Lugano, and 9Division of Infectious Diseases, Cantonal Hospital, St. Gall, Switzerland
Background. Little is known about time trends, predictors, and consequences of changes made to antiretroviral
therapy (ART) regimens early after patients initially start treatment.
Methods. We compared the incidence of, reasons for, and predictors of treatment change within 1 year after
starting combination ART (cART), as well as virological and immunological outcomes at 1 year, among 1866 patients
from the Swiss HIV Cohort Study who initiated cART during 2000 –2001, 2002–2003, or 2004 –2005.
Results. The durability of initial regimens did not improve over time (P  .15): 48.8% of 625 patients during
2000 –2001, 43.8% of 607 during 2002–2003, and 44.3% of 634 during 2004-2005 changed cART within 1 year;
reasons for change included intolerance (51.1% of all patients), patient wish (15.4%), physician decision (14.8%), and
virological failure (7.1%). An increased probability of treatment change was associated with larger CD4 cell counts,
larger human immunodeficiency virus type 1 (HIV-1) RNA loads, and receipt of regimens that contained stavudine
or indinavir/ritonavir, but a decreased probability was associated with receipt of regimens that contained tenofovir.
Treatment discontinuation was associated with larger CD4 cell counts, current use of injection drugs, and receipt of
regimens that contained nevirapine. One-year outcomes improved between 2000 –2001 and 2004 –2005: 84.5% and
92.7% of patients, respectively, reached HIV-1 RNA loads of50 copies/mL and achieved median increases in CD4
cell counts of 157.5 and 197.5 cells/L, respectively (P  .001 for all comparisons).
Conclusions. Virological and immunological outcomes of initial treatments improved between 2000 –2001 and
2004 –2005, irrespective of uniformly high rates of early changes in treatment across the 3 study intervals.
Combination antiretroviral therapy (cART) for the
treatment of human immunodeficiency virus (HIV) in-
fection has substantially reduced HIV-related morbidity
and mortality [1–3], and current guidelines suggest that
cART has to be continued throughout life [4]. In 1999,
we reported on initial experiences with cART in the
Swiss HIV Cohort Study during 1995–1998 and de-
scribed a substantial 1-year probability of treatment
change of 45.5% (95% confidence interval [CI], 43.5%–
47.5%) among the 2674 patients analyzed [5]. In the
subgroup of 1157 individuals who were treatment naive
before starting cART, the 1-year probability of treat-
ment change was 37.0% (95% CI, 34.1%– 40.1%). Over
the past few years, several new drugs with improved ef-
ficacy, tolerability, and more-convenient administra-
tion in terms of the number of pills, frequency of intake,
and restrictions in diet have become available. In light of
these improvements, we hypothesized that the durabil-
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ity of initial cART regimens has improved in recent years. To test
this hypothesis, we analyzed time trends of durability of initial
cART regimens, reasons for and predictors of early treatment
changes, and virological and immunological outcomes 12
months after the start of treatment.
PATIENTS AND METHODS
Patients. We selected patients who were participating in the
Swiss HIV Cohort Study, a prospective cohort with continual
enrollment of HIV-1–infected patients aged16 years [6]. Each
patient is followed up at 1 of 7 outpatient HIV clinics in cities
across Switzerland, including Zurich, Lausanne, Bern, Basel, Ge-
neva, St. Gallen, and Lugano, as well as at several affiliated hos-
pitals and private physicians’ offices. Clinical information is col-
lected prospectively on standardized questionnaires and
complemented with a semiannual structured interview and a set
of prespecified hematological, immunological, virological, and
serological analyses at least every 6 months. Since 2000, all dates
on which treatment with antiretroviral drugs was stopped and
started, including reasons for stopping, have been recorded by
the treating physicians as part of the Data Collection on Adverse
Events of Anti-HIV Drugs (DAD) protocol [7]. For each of 3
study periods—2000 –2001, 2002–2003, and 2004 –2005—we
focused the analyses on patients who were starting cART for the
first time. For a patient to be eligible for analysis, the dates on
which treatment was started and stopped had to be known, and
they could not have been lost to follow-up during the 1-year
period after initiating treatment. We excluded pregnant women
who had initiated ART for the prevention of mother-to-child
transmission, because such treatment is often discontinued after
birth if HIV infection does not require continued cART. The
study was approved by the local ethical review boards, and writ-
ten informed consent was obtained from all participants.
cART. We classified changes to cART as treatment switch
(i.e., replacement of at least 1 drug in the regimen), treatment
cessation or discontinuation for2 weeks (hereafter jointly re-
ferred to as “discontinuation”), and treatment intensification
(i.e., addition of new drugs to an otherwise unchanged regimen).
Discontinuation of treatment for2 weeks was not classified as
treatment change if the patient resumed the initial treatment;
however, if 1 or more drugs were replaced, such discontinuation
was classified as treatment switch. Reasons for switching or stop-
ping treatment were classified as (1) treatment failure, (2) intol-
erance or adverse events, (3) patient wish, (4) physician decision,
and (5) other.
We categorized cART regimens on the basis of the most fre-
quently used nucleoside reverse-transcriptase inhibitor (NRTI)
backbones (i.e., zidovudine/lamivudine, stavudine/lamivudine,
tenofovir/emtricitabine or lamivudine, and didanosine/another
NRTI) and third drugs (i.e., the nonnucleoside reverse-
transcriptase inhibitors (NNRTIs) efavirenz and nevirapine; the
protease inhibitors (PIs) lopinavir/ritonavir; nelfinavir, indina-
vir/ritonavir, and atazanavir/ritonavir, and the NRTI abacavir).
We also defined regimens with respect to class, as follows: triple-
NRTI treatment, PI-based treatment, NNRTI-based treatment,
or 3-class treatment.
Figure 1. Characteristics of combination antiretroviral therapy (cART) use and change among patients starting their first cART regimen.
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Hepatitis B virus (HBV) and hepatitis C virus (HCV)
infection. Patients were classified as having active HBV infec-
tion, if they tested positive for HBV surface antigen (HBsAg),
HBV e antigen (HBeAg), or HBV DNA; as vaccinated, if they
tested positive for anti-HBsAg and negative for antibody to HBV
core antigen (anti-HBc); as seropositive with inactive infection,
if they tested negative for HBsAg, HBeAg, and HBV DNA and
positive for anti-HBc; and as seronegative, if they tested negative
for anti-HBc. Patients were classified as having HCV coinfec-
tion, if they tested positive for antibody to HCV (anti-HCV) and
HCV RNA; they were classified as not having HCV coinfection,
if they tested negative for anti-HCV or if they tested positive for
anti-HCV and negative for HCV RNA.
End points. The primary end point was the first treatment
change during the 12-month period after starting cART. Sec-
ondary end points were virological and immunological treat-
ment responses 12 months after starting cART. Virological re-
sponse was defined as the suppression of the viral load to a level
less than the limit of detection (i.e.,50 copies/mL). Immuno-
logical response was defined as the median absolute CD4 cell
count at 12 months and the median increase in the CD4 cell
count between baseline and month 12 of cART. Individuals who
died within 1 year after starting treatment were considered for
analysis of the primary end point but excluded from analyses of
the secondary end points.
Statistical analyses. Time was measured from the start of
cART to the first treatment change 1 year later. Individuals
without treatment change within the 12-month interval were
censored after 12 months of therapy or on the date of death,
whichever occurred first. Kaplan-Meier curves were used to de-
scribe the cumulative incidence of treatment change on the basis
of study period, regimen type, backbone, and third drug. We
used log-rank tests and tests for trend to detect differences in the
Kaplan-Meier curves across the 3 study periods.
Table 1. Baseline characteristics of persons starting their first antiretroviral treatment regimen, by study
period.
Characteristic 2000–2001 2002–2003 2004–2005 P a
Male sex 430/625 (68.8) 420/607 (69.2) 445/634 (70.2) .86
Age
Included in analysis 625 607 634
Median (IQR), years 37 (32–44) 38 (32–45) 39 (33–47) .002
Race
White 492/625 (78.7) 467/607 (76.9) 489/634 (77.1) .95
Black 90/625 (14.4) 95/607 (15.7) 100/634 (15.8)
Other 43/625 (6.9) 45/607 (7.4) 45/634 (7.1)
Injection drug use
Never 485/625 (77.6) 512/607 (84.3) 535/634 (84.4) .009
Past historyb 51/625 (8.2) 36/607 (5.9) 41/634 (6.5)
Active 89/625 (14.2) 59/607 (9.7) 58/634 (9.1)
Body mass indexc
Included in analysis 623 607 634
Median (IQR) 22.1 (20.2–24.5) 22.6 (20.5–25.3) 22.8 (20.7–25.3) .006
Past history of clinically defined AIDS 184/625 (29.4) 151/607 (24.9) 155/634 (24.4) .085
HBV infection .007
Seronegative or vaccinated 280/609 (46.0) 304/598 (50.8) 342/618 (55.3)
Seropositive inactive 286/609 (47.0) 268/598 (44.8) 241/618 (39.0)
Current infection 43/609 (7.1) 26/598 (4.3) 35/618 (5.7)
Active HCV infection 138/621 (22.2) 88/601 (14.6) 99/626 (15.8) .001
HIV-1 RNA load
Included in analysis 510 521 573
Median (IQR), log10 copies/mL 4.9 (4.4–5.3) 5.0 (4.6–5.5) 5.1 (4.5–5.5) .003
CD4 cell count
Included in analysis 511 523 573
Absolute, median (IQR), cells/L 175 (72–289) 195 (102–291) 195 (101–270) .065
200 cells/L 298 (58.3) 269 (51.4) 297 (51.8) .044
NOTE. Data are no. of patients analyzed or no. of patients with the characteristic/no. analyzed (%), unless otherwise indicated.
HBV, hepatitis B virus; HCV, hepatitis C virus; IQR, interquartile range.
a By the test for trend.
b Includes patients who were participating in an opiate-maintenance program during the study period.
c Defined as the weight in kilograms divided by the height in meters squared.
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We used 2 and Fisher exact tests to compare proportions and
Wilcoxon and Kruskal-Wallis tests to compare continuous vari-
ables across different study groups. Time trends in virological
and immunological outcomes after 12 months of therapy were
assessed with 2 tests for linear trend, for the percentages of pa-
tients with an HIV-1 RNA load of50 copies/mL, and nonpara-
metric tests for trend, for the absolute CD4 cell counts at 12
months and changes in the CD4 cell count from baseline.
For the analysis of predictors of treatment change, we dis-
carded the group of patients for whom treatment change was
classified as treatment intensification, because of small sample
sizes (20 such patients for each study period). We assumed
that predictors for treatment switch differed from predictors for
treatment discontinuation and modeled these 2 competing out-
comes by means of multinomial logistic regression, using the
group of patients without a treatment change as the reference
group.
CD4 cell count strata (200, 200 –350, and 350 cells/L)
and HIV-1 RNA load strata (5 log10 copies/mL and 5 log10
copies/mL) were taken from the most recent treatment guide-
lines [4]. Additional covariables were age (per 10-year increase),
sex, clinically defined AIDS (i.e., Center for Disease Control and
Prevention stage C disease [8]), hepatitis B and/or C virus co-
infection, injection drug use (never, former or currently in an
opiate-maintenance program, and current), and antiretroviral
treatment.
We used Stata, version 9.2 (StataCorp), for all analyses. All P
values were calculated by 2-sided tests without correction for
multiple tests.
RESULTS
Characteristics of cART use and treatment change during the
study periods are outlined in figure 1. Of treatment-naive pa-
tients newly starting cART during the study intervals, 625
(86.9%) of 719 during 2000 –2001, 607 (91.4%) of 664 during
2002–2003, and 634 (87.7%) of 723 during 2004 –2005 were el-
igible for analysis. Baseline characteristics of the study popula-
tion are detailed in table 1. There was a significant increase in the
median age over the study periods. This finding is compatible
with a concomitant reduction in the proportion of younger in-
dividuals infected through injection drug use, owing to preven-
tion efforts such as needle exchange programs. This also explains
the reduction in the proportion of patients with active HCV
infection. Characteristics of the initial antiretroviral treatments
are given in table 2. The composition of antiretroviral regimens
Table 2. Characteristics of initial combination antiretroviral therapy received by persons
starting their first regimen, by study period.
Variable
2000–2001
(n  625)
2002–2003
(n  607)
2004–2005
(n  634) P
Regimen
Triple NRTI 44 (7.0) 48 (7.9) 22 (3.5) .001
PI based 366 (58.6) 259 (42.7) 307 (48.4)
NNRTI based 200 (32.0) 298 (49.1) 303 (47.8)
3 classes 15 (2.4) 2 (0.33) 2 (0.32)
NRTI backbone
Zidovudine/3TC 444 (71.0) 508 (83.7) 377 (59.5) .001
Stavudine/3TC 74 (11.8) 24 (4.0) 6 (0.95)
Tenofovir/FTC or 3TC 0 17 (2.8) 184a (29.0)
Didanosine/other NRTI 49 (7.8) 44 (7.2) 33 (5.2)
Other NRTI combinations 58 (9.3) 14 (2.3) 34 (5.4)
Third drug
Efavirenz 180 (28.8) 269 (44.3) 278 (43.8) .001
Lopinavir/ritonavir 31 (5.0) 186 (30.6) 230 (36.3)
Nelfinavir 228 (36.5) 65 (10.7) 12 (1.9)
Indinavir/ritonavir 80 (12.8) 4 (0.66) 1 (0.16)
Nevirapine 19 (3.0) 29 (4.8) 24 (3.8)
Abacavir 23 (3.7) 37 (6.1) 5 (0.79)
Atazanavir/ritonavir 0 1 (0.16) 48 (7.6)
Other unboosted PIs 27 (4.3) 1 (0.16) 9 (1.4)
Other boosted PIs 14 (2.2) 4 (0.66) 9 (1.4)
Other (including 3-class regimens) 23 (3.7) 11 (1.8) 18 (2.8)
NOTE. FTC, emtricitabine; NNRTI, nonnucleoside reverse-transcriptase inhibitors; NRTI, nucleoside or
nucleotide reverse-transcriptase inhibitors; PI, proteinase inhibitors; 3TC, lamivudine.
a Includes 134 patients who received 3TC and 50 patients who received FTC.
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changed significantly over time, mostly because of the introduc-
tion of new drugs (i.e., tenofovir, emtricitabine, and atazanavir),
an increased use of NNRTI-based regimens, and use of boosted
PIs.
Durability of initial cART. As shown in figures 1 and 2A,
the percentage of patients who changed treatment within the
first 12 months did not change significantly over the 3 periods:
48.8% (95% CI, 45.0%–52.8%) changed during 2000 –2001,
43.8% (95% CI, 39.8%– 47.7%) changed during 2002–2003, and
44.3% (95% CI, 40.6%– 48.3%) changed during 2004 –2005
(P  .15, by the test for trend). The 12-month probability of
treatment change for all 3 periods combined was 45.6% (95%
CI, 43.4%– 47.9%). The hazard of treatment change was higher
in the first 2 months (as shown by the steeper slope of the curve
during this period) and then remained constant through month
12 of treatment. Of interest, although no significant time trends
were present for the overall rates of treatment change, treatment
switch, or treatment intensification, the trend for treatment dis-
continuation over the 3 periods was highly significant, with 99
patients (15.8%) discontinuing cART during 2000 –2001, 59
(9.7%) discontinuing during 2002–2003, and 61 (9.6%) discon-
tinuing during 2004 –2005 (P  .0006).
The probabilities of treatment switch, by drug class, were also
very similar (figure 2B). At 12 months, 39.2% (95% CI, 36.1%–
42.4%) of PIs in PI-containing regimens, 34.3% (95% CI, 31.2%–
37.7%) of NNRTIs in NNRTI-containing regimens, and 33.7%
(95% CI, 31.6%–35.9%) of NRTIs had been modified. Substantial
differences, however, could be found in the analyses of the proba-
bility of discontinuation of individual drugs. The Kaplan-Meier
curves for individual NRTIs are displayed in figure 2C; Kaplan-
Meier curves for PIs and NNRTIs are displayed in figure 2D. The
12-month probabilities of discontinuation of NRTIs ranged from
19.7% (95% CI, 15.2%–25.3%) for tenofovir to 50.6% (95% CI,
43.4%–58.3%) for stavudine, and the 12-month probabilities of
discontinuation of PIs or NNRTIs ranged from 16.4% (95% CI,
9.7%–27.1%) for atazanavir to 42.9% (95% CI, 33.1%–54.1%) for
nevirapine. Formal significance testing of the differences was not
performed because the curves are not independent (i.e., each pa-
tient has data reflected in1 curve).
The analysis of 1-year discontinuation rates across the 3 peri-
ods showed significant increases for stavudine (45% [95% CI,
37%–54%], 64% [95% CI, 48%–79%], and 89% [95% CI, 61%–
99%], respectively, during 2000 –2001, 2002–2003, and 2004 –
2005; P  .0072, by the test for trend) and abacavir (27% [95%
CI, 17%–39%], 36% [95% CI, 27%– 49%], and 55% [95% CI,
38%–73%], respectively; P  .0031), a slight increase for lopi-
navir (23% [95% CI, 11%– 42%], 35% [95% CI, 29%– 42%],
and 40% [95% CI, 34%– 46%], respectively; P  .055), and a
significant decrease for lamivudine (28% [95% CI, 24%–31%],
22% [95% CI, 18%–25%], and 19% [95% CI, 16%–23%], re-
spectively; P  .0014).
Reasons for treatment change. Intolerance (51.1% of pa-
tients), patient wish (15.4%), and physician decision (14.8%)
were the most frequent reasons for treatment change within the
first year, and there was little variation across the 3 study periods
(figure 3A). Intolerance was the most frequent reason for treat-
ment switch (61.0%, 59.9%, and 57.2% of patients, respectively,
during 2000 –2001, 2002–2003, and 2004 –2005; P  .45, by the
Figure 2. Time to first combination antiretroviral treatment (cART) change, by study period (A), drug class (B), nucleoside or nucleotide reverse-
transcriptase inhibitor type (C), and nonnucleoside reverse-transcriptase inhibitor and protease inhibitor type (D).
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test for trend), followed by physician decision (12.8%, 15.2%,
and 21.4% of patients, respectively; P  .023). Virological or
immunological treatment failure became less than half as fre-
quent (11.8%, 8.6%, and 5.5% of patients, respectively, during
the 3 study periods; P  .027). The most frequent reasons for
treatment interruption were patient wish (38.4%, 37.3%, and
34.4% of patients, respectively, during the 3 study periods) and
intolerance (29.3%, 28.8%, and 29.5% of patients, respectively),
and there was no indication of a time trend (P  .1 for all com-
parisons).
Predictors of treatment change. Results from univariable
and multivariable multinomial logistic regression analyses of
predictors of switch and discontinuation in the first 12 months
of therapy are displayed in table 3. Higher baseline CD4 cell
counts, higher HIV-1 RNA loads, and regimens that contained
stavudine or indinavir/ritonavir were associated with an in-
creased risk of treatment switch, whereas NRTI backbones with
tenofovir/emtricitabine or tenofovir/lamivudine were associ-
ated with a lower risk. No demographic characteristics were as-
sociated with treatment switch, and we did not find increased
risks for injecting drug users or individuals coinfected with hep-
atitis viruses. However, current use of injection drugs was highly
associated with treatment discontinuation. Additional predic-
tors for discontinuation were higher CD4 cell counts and reg-
imens containing nevirapine. These predictors were present for
both female and male patients (data not shown).
Virological, immunological, and clinical outcomes after 12
months. Table 4 summarizes virological and immunological
outcomes across the 3 study periods 12 months after initiating
cART. Trend analyses showed significant improvements in viro-
logical efficacy (defined as achievement of an HIV-1 RNA load of
50 copies/mL) over time, ranging from 87.1% of patients with
any change in treatment to 96.9% with no change in treatment.
Immunological responses (defined as the increase in the CD4
cell count increase from baseline and the absolute CD4 cell
count at 12 months) generally exhibited similar patterns. Inter-
estingly, the increase in CD4 cell count over time were attenu-
ated in patients who did not change treatment. This could have
been the result of a saturation effect, given that the virological
response was 90% in all 3 periods, or could have been influ-
enced by the fact that treatment for patients with a higher CD4
cell count was more likely to be switched. Of note, a new clinical
AIDS-defining event was experienced by 37 patients (5.9%) dur-
ing 2000 –2001, 29 (4.8%) during 2002–2003, and 28 (4.4%)
during 2004 –2005, and 11 (1.8%), 8 (1.3%), and 8 (1.26%),
respectively, died before the end of the 12-month study interval.
The patients who died were not included in the outcome analy-
ses described above.
DISCUSSION
In this analysis of 1866 participants from the Swiss HIV Cohort
Study who first started cART between 2000 and 2005, we found
that a substantial percentage (45.6%) had their treatment
changed1 year after it was initiated. No significant difference
in the percentages of patients who changed treatment was ob-
served between the study periods, and treatment change was
more likely to occur among these patients than among those
who started their first cART regimen during 1995–1998, for
whom the probability of switching was 37.0% (B.L., unpub-
lished data) [5]. Similar time trends towards shorter times to
treatment change during recent years were described for the Vet-
erans Affairs virtual cohort and were attributed to an increase in
the number of alternative regimens [9]. During our study, the
Figure 3. Reasons for changing the initial antiretroviral treatment
regimen during the first year of therapy, by study period (A) and type of
treatment switch among 2-class regimens (B).
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Table 3. Multinomial logistic regression analysis of predictors of combination antiretroviral treatment (cART) switch and discontin-
uation during the first 12 months of cART among 1518 persons receiving their first regimen.
Predictor
Switch, analysis type Discontinuation, analysis type
Univariable Multivariable Univariable Multivariable
RRR (95% CI) P RRR (95% CI) P RRR (95% CI) P RRR (95% CI) P
Study period
2000–2001 1 NDa 1 NDa
2002–2003 1.15 (0.87–1.53) .33 NDa 0.67 (0.45–0.99) .044 NDa
2004–2005 1.10 (0.84–1.46) .48 NDa 0.57 (0.38–0.85) .005 NDa
Female sex 1.11 (0.87–1.42) .38 1.22 (0.94–1.57) .13 1.07 (0.75–1.53) .70 1.00 (0.68–1.48) .97
Age, per 10-year increase 1.05 (0.94–1.16) .42 1.04 (0.93–1.17) .45 0.85 (0.72–1.00) .055 0.91 (0.75–1.09) .30
Injection drug use
Never 1 1 1 1
Past or in DTP 1.14 (0.73–1.80) .56 1.40 (0.79–2.49) .25 2.64 (1.50–4.65) .001 1.84 (0.88–3.87) .11
Current 0.72 (0.48–1.08) .11 0.92 (0.54–1.58) .76 4.18 (2.80–6.23) .001 3.06 (1.65–5.67) .001
Active HBV infection 0.90 (0.55–1.45) .66 1.00 (0.60–1.64) .99 0.95 (0.48–1.91) .89 1.01 (0.49–2.10) .98
HCV infection 0.82 (0.60–1.12) .21 0.77 (0.48–1.24) .29 3.15 (2.21–4.49) .001 1.47 (0.82–2.66) .20
Previous diagnosis of
clinically defined AIDS 1.06 (0.80–1.41) .66 1.01 (0.75–1.37) .94 1.27 (0.86–1.88) .23 1.46 (0.95–2.25) .084
CD4 cell count, cells/ L
200 1.23 (0.95–1.59) .11 1.09 (0.83–1.43) .54 1.05 (0.72–1.54) .80 0.91 (0.60–1.39) .68
200–350 1 1 1 1
350 1.62 (1.14–2.31) .007 1.50 (1.04–2.17) .029 2.19 (1.36–3.51) .001 2.33 (1.41–3.86) .001
HIV-1 RNA load 5 log10
copies/mL 1.33 (1.07–1.67) .012 1.35 (1.07–1.71) .013 0.90 (0.65–1.26) .55 1.16 (0.81–1.65) .43
Regimen
PI based 1 NDa 1 NDa
NNRTI based 0.97 (0.77–1.22) .79 NDa 0.78 (0.55–1.11) .17 NDa
Triple NRTI 1.04 (0.60–1.79) .90 NDa 1.70 (0.89–3.27) .11 NDa
3 classes 11.0 (1.32–92.2) .027 NDa 4.75 (0.29–76.6) .27 NDa
NRTI backbone
Zidovudine/3TC 1 1 1 1
Stavudine/3TC 1.26 (0.78–2.03) .34 1.57 (0.93–2.66) .091 1.11 (0.55–2.26) .77 1.28 (0.59–2.79) .54
Tenofovir/FTC or 3TC 0.56 (0.39–0.82) .003 0.65 (0.43–0.97) .035 0.50 (0.27–0.91) .024 0.56 (0.29–1.10) .094
Didanosine/other NRTI 1.83 (1.16–2.90) .009 2.06 (1.29–3.31) .003 1.88 (1.00–3.50) .048 1.71 (0.87–3.34) .12
Other NRTI
combinations 1.26 (0.72–2.20) .42 1.21 (0.67–2.21) .53 1.41 (0.66–3.02) .38 1.37 (0.59–3.18) .46
Third drug
Efavirenz 1 1 1 1
Lopinavir/ritonavir 1.16 (0.88–1.54) .29 1.09 (0.81–1.45) .57 1.25 (0.80–1.95) .34 1.10 (0.69–1.75) .70
Nelfinavir 0.93 (0.66–1.31) .68 0.81 (0.57–1.15) .24 1.99 (1.26–3.12) .003 1.52 (0.93–2.47) .096
Indinavir/ritonavir 2.65 (1.47–4.77) .001 2.28 (1.24–4.17) .008 1.96 (0.76–5.07) .17 1.17 (0.43–3.16) .76
Nevirapine 1.02 (0.54–1.92) .95 0.94 (0.49–1.79) .85 2.74 (1.32–5.67) .007 2.41 (1.10–5.25) .027
Abacavir 0.73 (0.36–1.49) .38 0.78 (0.37–1.61) .50 2.36 (1.09–5.12) .029 1.85 (0.81–4.21) .14
Atazanavir/ritonavir 0.41 (0.18–0.94) .034 0.52 (0.22–1.26) .15 0.83 (0.28–2.44) .74 1.02 (0.31–3.29) .98
Other unboosted PIs 0.48 (0.18–1.30) .15 0.36 (0.13–1.03) .058 0.34 (0.05–2.60) .30 0.24 (0.03–1.97) .19
Other boosted PIs 1.05 (0.38–2.87) .93 0.99 (0.34–2.84) .98 1.87 (0.50–6.91) .35 1.31 (0.32–5.40) .71
Other, including 3-class
regimen 2.27 (1.00–5.15) .051 1.97 (0.84–4.58) .12 2.49 (0.77–8.10) .13 1.70 (0.47–6.16) .42
NOTE. Patients for whom cART did not change served as the reference group. Patients with treatment intensification and patients with incomplete sets of
covariables were excluded from the analysis. See Patients and Methods for definitions of cART switch and discontinuation. CI, confidence interval; DTP,
opiate-maintenance program; HBV, hepatitis B virus; HCV, hepatitis C virus; NRTI, nucleoside or nucleotide reverse-transcriptase inhibitor; NNRTI, nonnucleoside
reverse-transcriptase inhibitor; PI, proteinase inhibitor; RRR, relative risk ratio.
a Collinear with several other variables, especially individual drugs (i.e., those in NRTI backbones or third drugs).
number of alternative regimens prescribed for1% of patients
increased from 11 during 2000 –2001 and 2002–2003 to 16 dur-
ing 2004 –2005. At a recent conference, Egger [10] highlighted
an association between the probability of treatment change and
the number of alternative regimens by showing that the rate of
treatment change in South Africa (22% within 12 months after
initiating therapy), where there are few cART alternatives, is
about half the rate observed in Switzerland, where there are
many alternatives.
We have shown that newer drugs, such as atazanavir (which
was not approved for first-line treatment in Switzerland during
the periods analyzed) and tenofovir, that are part of first-line
regimens are changed less often, but this had not yet translate
into a reversal of time trends, because the number of patients
starting with such combinations was still relatively small and
limited to the most recent period analyzed. We did, however,
observe a clear reduction in discontinuation rates for lamivu-
dine, which parallels the increased use of lamivudine/tenofovir
and the decreased use of lamivudine/stavudine.
Unlike other studies of treatment switching, this analysis fo-
cused on predictors of 2 distinct outcomes, treatment change
and treatment discontinuation, in multinomial logistic regres-
sion models. Demographic characteristics such as age, sex, injec-
tion drug use, and disease stage did not appear to affect the prob-
ability of treatment change. However, compared with patients
with a CD4 cell count of 200 –350 cells/L at baseline, individ-
uals with counts of 350 cells/L were more likely to change
treatment (multivariable relative risk ratio, 1.62; P  .029).
This difference is reflected in the reason for treatment change,
with higher percentages of changes occurring because of intol-
erance (66.2% vs. 62.1%) and patient wish (12.5% vs. 6.8%)
among patients with a CD4 cell count of 350 cells/L than
among those with a count of 200 –350 cells/L. The higher rates
of treatment changes among patients with a baseline HIV-1
RNA load of 5 log10 copies/mL, however, are predominantly
attributable to intolerance (62.0% for an HIV-1 RNA load of5
log10 copies/mL vs. 54.6% for a load of5 log10 copies/mL).
We found higher rates of treatment changes for regimens con-
taining didanosine or ritonavir-boosted indinavir, both of
which, according to current guidelines, are no longer recom-
mended as constituents of initial therapy, because of their
greater potential for toxicity [4].
We did not find evidence of increased rates of treatment
change among patients with HBV or HCV coinfection. This
finding differs from data reported by the EuroSIDA study group
[11, 12] but concurs with data from the University of North
Carolina Center for AIDS Research [13]. On the other hand,
univariable analysis revealed that HCV coinfection and injection
Table 4. Virological and immunological outcomes 12 months after initiation of combination antiretroviral
therapy (cART) among persons receiving their first regimen, by study period.
cART change status, outcome 2000–2001 2002–2003 2004–2005 P a
Overall, intent-to-treat
HIV-1 RNA load 50 copies/mL 503/595 (84.5) 532/587 (90.6) 567/612 (92.6) .001
CD4 cell count, cells/L
Increase from baseline 157.5 (70–272) 176.5 (72–288) 197.5 (110–302) .001
Absolute, month 12 336.5 (219–523) 371 (233–533) 393 (277–525) .001
No change
HIV-1 RNA 50 copies/mL 288/319 (90.3) 321/338 (95.0) 338/349 (96.9) .001
CD4 cell count, cells/L
Increase from baseline 183 (87.5–302.5) 184 (99–296) 203.5 (117–300) .20
Absolute, month 12 369 (243–534) 374 (246–536) 394 (270–511) .59
Any change, intent-to-treatb
HIV-1 RNA load 50 copies/mL 215/276 (77.9) 211/249 (84.7) 229/263 (87.1) .004
CD4 cell count, cells/L
Increase from baseline 132 (44–220) 145 (49–266) 193.5 (94–315) .001
Absolute, month 12 305 (193–478) 360 (222–533) 390 (279–571) .001
Switch or intensificationc
HIV-1 RNA load 50 copies/mL 175/200 (87.5) 186/201 (92.5) 202/215 (94.0) .020
CD4 cell count, cells/L
Increase from baseline 148.5 (92–236) 171 (58–286) 200 (121–318) .003
Absolute, month 12 305 (193–457) 362 (213–540) 387 (277–566) .001
NOTE. Data no. of patients with the characteristic/no. analyzed (%) or median (interquartile range). See Patients and
Methods for definitions of cART change.
a By tests for trend across the 3 study periods.
b Including persons who discontinued cART.
c Excluding persons who discontinued cART.
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drug use appeared to affect the probability of treatment discon-
tinuation. In the multivariable model, only current injection
drug use was significantly associated with treatment interrup-
tion. Conclusions need to be drawn with caution, because injec-
tion drug use and HCV coinfection are highly collinear. Reasons
for treatment discontinuation tend to support the hypothesis
that lifestyle or dependency-related personal motivations, rather
than HCV-associated problems, lead to an increased probability
of treatment discontinuation: among patients without and pa-
tients with HCV infection, intolerance was stated as the reason
for treatment discontinuation for 28.4% and 30.7%, respectively
(P  .72), and patient wish was cited for 30.5% and 49.3%, re-
spectively (P  .006).
Favorable time trends could be shown for virological and im-
munological efficacy, in terms of both the frequency of treat-
ment change owing to treatment failure and the HIV-1 RNA
load and CD4 cell count after 12 months of treatment. In the
intent-to-treat population who began treatment during 2004 –
2005, the percentage of patients with an HIV-1 RNA load of50
copies/mL at 1 year of treatment (92.6% [567 patients]) was
higher than that reported in randomized clinical trials [14 –17].
In the AIDS Clinical Trials Group A5095 study [15], for exam-
ple, the combination of zidovudine/lamivudine/efavirenz,
which was also frequently used in our study, resulted in viral
loads of 50 copies/mL at 48 weeks in 80%–90% of patients,
even when missing data were ignored. The per-protocol analysis
from the KLEAN (Kaletra versus Lexiva with Epivir and abacavir
in ART-naive patients) study, which compared ritonavir-
boosted fosamprenavir with lopinavir, showed that 88% and
89% of patients, respectively, achieved HIV-1 RNA loads of50
copies/mL [14]. The difference may partly be explained by the
selection criteria we used in our study. Indeed, if we assume that
all 22 individuals from the 2004 –2005 group with no HIV-1
RNA data at 1 year had a viral load of50 copies/mL, the success
rate decreases to 89.4% (567 of 634 patients), and if, in addition,
all 43 patients during this period who were lost to follow-up did
not have a virological response, the success rate decreases to
83.4% (567 of 677 patients).
The strength of this clinic-based study is its representativity:
almost 70% of all persons with AIDS (i.e., CDC stage C disease)
in Switzerland are included. Although we have tried to limit the
number of excluded patients, a small bias introduced by individ-
uals lost to follow-up cannot be excluded. Another limitation is
related to the coding of reasons for discontinuation of individual
drugs, which is often multifaceted, especially if no obvious
events such as virological failure or acute adverse events are
present. Because there is no code for treatment simplification
(such as a convenience switch to a once-daily regimen), the rea-
son given for such a change may be specified as either patient
wish or physician decision. Unfortunately, we could not include
information on adherence to cART, because collection of this
information only started in May 2003.
The decision about when and how to start antiretroviral treat-
ment is often the result of a long dialogue between physicians
and their patients, during which the pros and cons of early versus
deferred initiation and of different regimens are weighed with
regard to expected adverse effects, pill burden, and mode of in-
take. Fortunately, differences in the antiviral activity of currently
recommended initial regimens, if present at all, are negligible.
Ideally, the first regimen should last for many years, because
intolerance may, for some patients, lead to discouragement and
negatively impact their commitment to treatment, including ad-
herence. Indeed, we found the best 1-year virological outcome
among individuals for whom treatment did not change. How-
ever, virological outcome was almost similarly excellent among
persons who changed their initial treatment early during the
course of cART.
In conclusion, we found that the frequency of early treatment
change after initiation of antiretroviral therapy did not decrease
between 2000 and 2005 but that, nevertheless, virological and
immunological outcomes improved over time.
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